SATOREOTIDE TRIZOXETAN

Breast Cancer

Ipsenprotein_peptidePhase 2Dormant

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 27/ 100
Competitive Position: 59/ 100

Competitive context

891 Active assets in the Breast Cancer cohort.

Asset / Sponsor	Phase	Rating
Lapatinib University of New Mexico	Phase 3	BBB
Darolutamide Vandana Abramson	Phase 2	BBB
Trastuzumab Duocarmazine Byondis B.V.	Phase 3	BB
ERIBULIN MONOMETHANESULFONATE Henan Cancer Hospital	Phase 4	BB
Palbociclib Hoffmann-La Roche	Phase 4	BB

View all 50 →

Same molecule, other indications

SATOREOTIDE TRIZOXETAN is also rated in:

digestive system neuroendocrine neoplasmDormant

CC

Indicative ·

41 / 100

Small Cell Lung Cancer and Breast CancerDormant

C

Indicative ·

39 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.